Mira Hellmann, MD, discusses using trametinib to treat patients with low-grade ovarian serous carcinomas.
Mira C. Hellmann, MD
Advertisement
Articles by Mira C. Hellmann, MD
Mira C. Hellmann, MD, discusses the benefit of PARP inhibitors in patients with ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Hellmann on Benefit of PARP Inhibitors in Patients With Ovarian CancerPublished: March 3rd 2020 | Updated:
Dr. Hellmann on Using Trametinib in Low-Grade Ovarian Serous CarcinomaPublished: March 13th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5